H.C. Wainwright initiated coverage of Coya Therapeutics with a Buy rating and $18 price target. Coya is an emerging biotech company focused on treating neurological conditions using novel immunomodulatory approaches, the analyst tells investors in a research note. The firm says Coya is developing proprietary products focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COYA: